This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.
Metastatic Urothelial Carcinoma
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center
After decades of no new approvals for the treatment of metastatic urothelial cancer, a malignancy associated with a low survival rate, novel immunotherapeutic agents are changing the treatment landscape for bladder cancer. Learn about the therapies showing activity in this malignancy and get clinical pearls on how to manage a patient with urothelial cancer with immune-related hepatitis and pancreatitis.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |